Stockscreener 앱 받기
0.00
100.00%
-14.00
전일 마감가:
$14.00
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$1.00B
수익:
-
순이익/손실:
$-192.96M
주가수익비율:
0.00
EPS:
-3.3
순현금흐름:
$-167.04M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$14.00
52주 변동 폭
$0.00
$25.00
Ventyx Biosciences Inc Stock (VTYX) Company Profile
명칭
Ventyx Biosciences Inc
전화
(760) 407-6511
주소
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Compare VTYX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
0.00 | 1.00B | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-05 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-03-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-03-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-11-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-07 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-11-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-11-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Wells Fargo | Overweight |
| 2022-12-19 | 개시 | Goldman | Buy |
| 2022-11-17 | 개시 | Morgan Stanley | Overweight |
| 2022-09-07 | 개시 | Stifel | Buy |
| 2022-09-01 | 개시 | H.C. Wainwright | Buy |
| 2022-05-09 | 개시 | Credit Suisse | Outperform |
| 2022-03-31 | 개시 | Canaccord Genuity | Buy |
| 2022-02-01 | 개시 | Oppenheimer | Outperform |
| 2021-11-15 | 개시 | Jefferies | Buy |
| 2021-11-15 | 개시 | Piper Sandler | Overweight |
모두보기
Ventyx Biosciences Inc 주식(VTYX)의 최신 뉴스
Ventyx Biosciences (VTYX) exec records option dispositions in $14 Lilly buyout - Stock Titan
Ventyx Biosciences (VTYX) cashed out at $14 per share in Eli Lilly merger - Stock Titan
COO’s Ventyx (VTYX) options cashed out as Eli Lilly merger closes - Stock Titan
Lilly–Ventyx (VTYX) merger cancels director stock options at $14 - Stock Titan
Ventyx Biosciences (VTYX) director’s options cancelled in Eli Lilly cash merger - Stock Titan
Ventyx (VTYX) director’s options and shares cashed out at $14 in Eli Lilly merger - Stock Titan
Eli Lilly deal converts Ventyx (VTYX) CMO’s shares and options to cash - Stock Titan
Eli Lilly and Company completed the acquisition of Ventyx Biosciences, Inc. from New Science Ventures, LLC, Affinity Asset Advisors, LLC, The Vanguard Group, Inc., and others. - marketscreener.com
Ventyx Biosciences (VTYX) deregisters registered resale shares after merger - Stock Titan
Ventyx Biosciences (NASDAQ: VTYX) deregisters shares after Eli Lilly merger - Stock Titan
Ventyx Biosciences completes $1.2 billion acquisition by Eli Lilly, delists from Nasdaq - Investing.com India
Ventyx Biosciences (VTYX) notifies Nasdaq of common stock delisting - Stock Titan
Ventyx Biosciences Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Ventyx Biosciences (NASDAQ: VTYX) shareholders get $14 cash in Eli Lilly buyout - Stock Titan
VTYX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Ventyx Biosciences Shareholders Approve Merger With Eli Lilly - TipRanks
Ventyx Biosciences shareholders approve merger with Eli Lilly - Investing.com
Ventyx Biosciences (VTYX) investors approve Eli Lilly merger and executive pay - Stock Titan
Insider Sell: Is Skyward Specialty Insurance Group Inc attractive at current valuationWeekly Trend Recap & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
VTYX Should I Buy - Intellectia AI
Ventyx Biosciences Inc. (VTYX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Best Pharmaceutical Stocks To Follow NowFebruary 27th - MarketBeat
Ventyx Biosciences (NASDAQ:VTYX) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
GLAZER CAPITAL, LLC Acquires Significant Stake in Ventyx Biosciences Inc - GuruFocus
Ventyx Faces Eli Lilly Acquisition, Delisting and Litigation - TipRanks
Ventyx Biosciences agrees to $14.00 cash per share merger with Eli Lilly; HSR waiting period cleared - TradingView
242,229 Shares in Ventyx Biosciences, Inc. $VTYX Acquired by GSA Capital Partners LLP - MarketBeat
Monaco Asset Management SAM Sells 536,288 Shares of Ventyx Biosciences, Inc. $VTYX - MarketBeat
Does Ventyx Biosciences Inc. meet Warren Buffett’s criteria2025 Top Gainers & Stock Portfolio Risk Control - mfd.ru
Ventyx Biosciences, Inc. $VTYX Shares Sold by Cibc World Market Inc. - MarketBeat
Ventyx Biosciences (VTYX) to Release Earnings on Thursday - MarketBeat
Growth Value: Is Ventyx Biosciences Inc currently under institutional pressureWeekly Stock Report & Smart Money Movement Tracker - baoquankhu1.vn
Eli Lilly acquires Ventyx Biosciences in $1.2bn deal - Financier Worldwide
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Consensus Recommendation of "Reduce" from Brokerages - MarketBeat
Can Ventyx Biosciences Inc. stock hit record highs againQuarterly Portfolio Summary & Free Community Supported Trade Ideas - mfd.ru
Eli Lilly, Ventyx Biosciences receive early termination from US FTC - MLex
Halper Sadeh LLC is Investigating Whether VAL, STKL, VTYX are Obtaining Fair Deals for their Shareholders - GlobeNewswire
VTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Ventyx Biosciences, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investi - The National Law Review
Panic Selling: Does Ventyx Biosciences Inc have a sustainable dividendForecast Cut & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc.VTYX - Business Wire
Halper Sadeh LLC Encourages STEL, GORO, SKYT, VTYX Shareholders to Contact the Firm to Discuss Their Rights - InsideNoVa.com
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--SKYT, GORO, STEL, and VTYX - Benzinga
Does Ventyx Biosciences Inc offer margin of safetyWeekly Profit Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Lilly-Ventyx US premerger waiting period set to expire Feb. 23 - MLex
Ventyx Biosciences Sets March 3, 2026 Vote on Eli Lilly $14-Per-Share Cash Merger - TipRanks
Aug Movers: Is QMCO stock a hidden gemEarnings Performance Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Chipmakers Recap: Does Ventyx Biosciences Inc meet Warren Buffetts criteriaJuly 2025 Technicals & Growth Focused Entry Reports - baoquankhu1.vn
Short Interest in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Drops By 37.7% - MarketBeat
Will Ventyx Biosciences Inc. benefit from rate cutsEarnings Beat & Daily Price Action Insights - mfd.ru
Halper Sadeh LLC Encourages NATH, VTYX, SKYT Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
Ventyx Biosciences Inc (VTYX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ventyx Biosciences Inc 주식 (VTYX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mohan Raju | CEO AND PRESIDENT |
Dec 18 '25 |
Sale |
7.72 |
47,345 |
365,461 |
2,372,863 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Dec 17 '25 |
Option Exercise |
0.00 |
34,930 |
0 |
502,156 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Dec 18 '25 |
Sale |
7.72 |
12,675 |
97,840 |
489,481 |
0.11%
6.00%
자본화:
|
볼륨(24시간):